Enclomiphene for women: fertility, PCOS, and off-label use

Most people who hear about enclomiphene think of men and low testosterone. The drug got its reputation by restoring endogenous testosterone without killing fertility. But the parent molecule, clomiphene, was first approved in 1967 for female infertility, and the enclomiphene isomer is the active half that drives most of the ovulation effect.

This guide covers what enclomiphene does in women, why physicians sometimes prescribe it off-label for PCOS-related anovulation, how dosing protocols compare to clomid, and why letrozole has taken over as the first-line choice. If youre here because a provider mentioned enclomiphene for fertility, youll also see where the real evidence stops and the marketing starts.

How SERMs work in women vs men

Selective estrogen receptor modulators (SERMs) block estrogen at the hypothalamus. The brain reads this as low estrogen and cranks up gonadotropin-releasing hormone (GnRH), which raises follicle-stimulating hormone (FSH) and luteinizing hormone (LH). That hormonal push is what restarts the reproductive axis in both sexes.

In men, higher LH tells the Leydig cells to make more testosterone. In women, higher FSH recruits ovarian follicles, and the mid-cycle LH surge triggers ovulation. Same drug, same upstream mechanism, different downstream target tissue.

Clomiphene citrate is a 38:62 mix of two isomers: enclomiphene (the trans form) and zuclomiphene (the cis form). Enclomiphene clears the body in about 10 hours. Zuclomiphene has a half-life of several weeks and lingers in tissue, which researchers blame for hot flashes, mood swings, and the anti-estrogenic uterine and cervical effects that can actually reduce fertility despite successful ovulation.

Enclomiphene for PCOS ovulation induction

PCOS is the most common cause of anovulatory infertility. Women with PCOS often have elevated LH relative to FSH, insulin resistance, and immature follicles that stall before releasing an egg. Raising FSH with a SERM can push those follicles to maturity.

Clomiphene was the first-line PCOS treatment under ACOG guidelines for decades. In the classic dataset from Kousta et al. (Hum Reprod, 1997), 70 to 80% of anovulatory women ovulated on clomiphene and 40 to 50% conceived within six cycles. The gap between ovulation and conception is real and comes partly from zuclomipheneʼs anti-estrogenic effect on cervical mucus and the endometrium.

Thats the theoretical case for pure enclomiphene. Remove the long-lasting isomer, keep the ovulation induction, and you get cleaner endometrial development and cervical mucus that actually lets sperm through. Small studies in men have confirmed better tolerability. Head-to-head female fertility data is sparse, which is why it remains off-label.

Dosing protocols for fertility

Fertility dosing looks nothing like the daily protocols used for male TRT alternatives. Women take a SERM for five days per cycle, then stop and wait for the follicle to mature and release.

The two standard cycle day windows are days 2 through 6 (earlier in the follicular phase) or days 3 through 7. Some clinics prefer days 5 through 9 for specific follicular timing. Monitoring usually includes a baseline ultrasound and basal labs, then follicle tracking around cycle day 12 to 14.

Cycle	Clomiphene dose	Enclomiphene dose (off-label)	Days	Next step if no ovulation
Cycle 1	50 mg daily	12.5 to 25 mg daily	Days 2 to 6 or 3 to 7	Increase dose next cycle
Cycle 2	100 mg daily	25 to 37.5 mg daily	Days 2 to 6 or 3 to 7	Increase if well tolerated
Cycle 3	150 mg daily (max)	37.5 to 50 mg daily	Days 2 to 6 or 3 to 7	Switch to letrozole or gonadotropins
Cycle 4 to 6	Continue effective dose	Continue effective dose	Days 2 to 6 or 3 to 7	Reassess; most conceptions happen by cycle 6

Enclomiphene monotherapy for female fertility is not standardized. The doses above reflect how some clinics approximate the enclomiphene fraction of a clomid dose, but your OB/GYN will set the protocol based on your ovarian reserve, BMI, and PCOS phenotype.

Success rates and timeline

Ovulation and pregnancy are two different endpoints, and the numbers diverge quickly. Kousta et al. reported 70 to 80% ovulation rates with clomiphene, 40 to 50% conception over six cycles, and roughly 30 to 40% live birth rates. If you ovulate in cycle one or two, expect to continue on the same dose. If you ovulate but dont conceive after three to six cycles, most reproductive endocrinologists move to intrauterine insemination (IUI) or switch agents.

The classic Legro et al. trial (NEJM, 2014) changed this equation for PCOS specifically. Letrozole produced a 27.5% live birth rate versus 19.1% for clomiphene over five cycles. Thats an 8.4 percentage point absolute advantage, which is why ACOG and the ASRM updated their recommendations.

For pure enclomiphene, there is no equivalent large randomized trial in female fertility. Case series and small cohorts suggest comparable ovulation rates to clomiphene with fewer endometrial complaints, but nothing on the scale needed to change guidelines. If youre weighing options, the most evidence-backed path for PCOS is letrozole first, clomiphene second, enclomiphene only in specific off-label scenarios.

Side effects specific to women

Side effects in women differ from the male TRT alternative use pattern. Some are mechanism-related and show up with any SERM. Others are specific to zuclomiphene accumulation, which is the theoretical reason to prefer pure enclomiphene.

Multiple pregnancy risk is real. Clomiphene carries a 5 to 10% twin rate and under 1% triplet rate, because it can recruit more than one dominant follicle. Ovarian hyperstimulation syndrome (OHSS) is rare with oral SERMs but can happen. Functional ovarian cysts appear in about 5 to 15% of cycles and usually resolve on their own.

Hot flashes hit 10 to 20% of women on clomiphene and tend to be milder on enclomiphene monotherapy. Mood changes (irritability, low mood, anxiety) appear in roughly 5 to 10% of users and are often reduced when zuclomiphene is removed. Visual disturbances (blurring, scotomas) are rare but require stopping the drug. Thickened cervical mucus and thin endometrium are the infamous anti-fertility side effects of long-acting zuclomiphene, and avoiding those is the main clinical argument for pure enclomiphene.

Why letrozole is now first-line for PCOS

Letrozole is an aromatase inhibitor, not a SERM. It blocks the conversion of androgens to estrogen, which drops estrogen levels and prompts the same FSH rise that drives ovulation. Unlike clomiphene, letrozole clears quickly and does not block estrogen receptors in the uterus or cervix.

The Legro trial (NEJM, 2014) randomized 750 women with PCOS to letrozole 2.5 to 7.5 mg or clomiphene 50 to 150 mg over five cycles. Letrozole won on live birth (27.5% vs 19.1%), ovulation rate (61.7% vs 48.3%), and had lower twin rates. Side effect profiles were similar.

ACOG and the ASRM now recommend letrozole as first-line for PCOS-related anovulation. Clomiphene remains a reasonable second choice, and enclomiphene sits further down the decision tree as an off-label alternative when mood side effects from clomid were intolerable. If youre starting treatment for PCOS infertility, ask your OB/GYN about letrozole first. You can read more about the menʼs-health side of these SERMs in the complete guide to enclomiphene and the direct enclomiphene vs clomid comparison. For women-specific hormone content, see the womenʼs health hub.

Frequently asked questions

Is enclomiphene FDA-approved for women?

No. Clomiphene citrate (Clomid) is FDA-approved for female infertility. Enclomiphene alone has never completed the Phase 3 trials needed for any FDA indication, female or male. Any use in women is off-label and typically requires a compounding pharmacy.

Can I get enclomiphene for fertility through telehealth?

Usually not. Most telehealth platforms that carry enclomiphene prescribe it for male hypogonadism, not female fertility. Fertility treatment needs an OB/GYN or reproductive endocrinologist who can monitor cycles with ultrasound and labs. You can search verified providers in our directory and start an evaluation through FormBlends.

Will enclomiphene help me get pregnant faster than clomid?

Probably not on ovulation rates, which look similar. It may help on endometrial thickness and cervical mucus quality because it avoids zuclomiphene accumulation. No randomized trial has shown a clear live-birth advantage over clomiphene in women.

What about letrozole, is that better?

For PCOS specifically, yes. The Legro trial (NEJM, 2014) showed letrozole produces higher live birth rates (27.5% vs 19.1%) than clomiphene. ACOG and the ASRM recommend letrozole as first-line for PCOS anovulation. Ask your provider about letrozole before starting a SERM.

What are the chances of twins on enclomiphene?

Data comes from the clomiphene literature, where twin rates run 5 to 10% and triplets under 1%. Pure enclomiphene is expected to behave similarly because the FSH-driven follicular recruitment mechanism is the same. Ultrasound monitoring reduces the risk of high-order multiples.

How long should I stay on enclomiphene before switching?

Most reproductive endocrinologists try three to six ovulatory cycles. If you ovulate but dont conceive after six cycles, or if you dont ovulate after dose escalation, the next step is usually IUI, injectable gonadotropins, or IVF. Staying on an oral SERM past six cycles rarely improves odds.

Can enclomiphene cause birth defects?

Clomiphene is Pregnancy Category X and must not be taken during pregnancy. Women confirm non-pregnancy before each cycle. Large datasets on clomiphene have not shown a clear increase in major birth defects when used correctly. Enclomiphene has a similar regulatory profile and the same rule applies.

What bloodwork do I need before starting?

Baseline FSH, LH, estradiol, prolactin, TSH, and often AMH to estimate ovarian reserve. A pelvic ultrasound confirms antral follicle count and rules out ovarian cysts. Your OB/GYN may also test for thyroid disease and insulin resistance if PCOS is suspected.

Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before starting any medication. Individual results vary. FormBlends is a licensed telehealth platform; nothing here replaces a personal clinical evaluation. Last reviewed 2026-04-17.